


## Bretylium tosylate

<b>Cat. No.:</b>	HY-12961A		
<b>CAS No.:</b>	61-75-6		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>24</sub> BrNO <sub>3</sub> S		
<b>Molecular Weight:</b>	414.36		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 30 mg/mL (72.40 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4134 mL	12.0668 mL	24.1336 mL
	5 mM	0.4827 mL	2.4134 mL	4.8267 mL
	10 mM	0.2413 mL	1.2067 mL	2.4134 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Bretylium (tosylate) is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters. It is the sympathetic nerve and adrenergic ganglion blocking agent. (1) Bretylium tosylate inhibits adrenergic function presynaptically only after an initial release in neurotransmitter substance. (2) The reference for administration dose is 15 mg/kg (I.P).

### REFERENCES

- [1]. McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. *J Physiol*. 2014 Jun 15;592(12):2667-78.
- [2]. Tew GA et al. Aging and aerobic fitness affect the contribution of noradrenergic sympathetic nerves to the rapid cutaneous vasodilator response to local heating. *J Appl Physiol* (1985). 2011 May;110(5):1264-70
- [3]. Cakir B et al. Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. *Physiol Res*. 2007;56(3):315-22. Epub 2006 Jun 22.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA